TALENTOP trial: conversion surgery in advanced HCC

Background

The management of advanced hepatocellular carcinoma (HCC) has changed markedly since 2020. Advanced HCC is defined by the Barcelona Clinic Liver Cancer (BCLC) staging system as the presence of vascular invasion, extrahepatic spread, and cancer-related symptoms. Sorafenib was the only therapy that showed a survival benefit until the publication of the IMbrave 150 trial, which demonstrated that atezolizumab plus bevacizumab outperformed sorafenib. Subsequent combinations-tremelimumab with durvalumab (STRIDE), camrelizumab with rivoceranib (CARES-310), and nivolumab with ipilimumab (CheckMate 9DW)-have also shown significant improvements in overall survival versus sorafenib-lenvatinib. These regimens have produced unprecedented objective response rates and durable disease control, sparking interest in conversion resection for patients whose tumours are down-staged or downsized after immunotherapy.

TALENTOP Study Design

The TALENTOP study, reported in a comment by Alejandro Fornera and colleagues in The Lancet (published 22 August 2026), is a multicentre, open-label, randomised, phase 3 trial. It compares liver resection after a course of atezolizumab and bevacizumab with maintenance therapy in patients with locally advanced HCC. The trial is positioned within the broader context of evolving first-line treatments for unresectable HCC and aims to assess whether surgical conversion after immunotherapy can improve outcomes. For details on the trial’s patient cohort, see the stats section. The study’s design and endpoints are aligned with the EASL-AASLD-ILCA consensus statement on trial design in HCC.

Implications for Conversion Surgery

The comment highlights that the combination of atezolizumab and bevacizumab has led to a new era of conversion surgery. By down-staging tumours, patients may become eligible for curative resection, a strategy that was previously limited to early-stage disease. The TALENTOP trial is the first large, randomised study to directly compare surgical conversion with continued systemic maintenance, providing evidence that may reshape treatment algorithms. The authors note that the study’s findings are consistent with earlier reports of high objective response rates in immunotherapy-treated HCC, such as those from the STRIDE, CARES-310, and CheckMate 9DW trials.

Future Directions

The TALENTOP study is part of a growing body of evidence that immunotherapy can transform the therapeutic landscape of advanced HCC. Future research will need to refine patient selection for conversion surgery, optimise peri-operative management, and integrate emerging biomarkers. The authors encourage continued collaboration across centres, as exemplified by the multicentre nature of the trial, to validate these findings in broader populations. For a broader view of ongoing trials and their outcomes, consult the fixtures and squad pages. The evolving role of conversion surgery will likely be reflected in upcoming updates to the BCLC strategy for prognosis prediction and treatment recommendations.